<p><a href="http://us.rd.yahoo.com/dailynews/rss/business/*http://news.yahoo.com/s/nm/20080804/bs_nm/imclone_dc"><img src="http://d.yimg.com/us.yimg.com/p/nm/20080804/2008_08_04t150021_450x300_us_imclone.jpg?x=130&y=8 6&q=85&sig=fPlF2xRgV1ij3LJSQ7Tc1A--" align="left" height="86" width="130" alt="A laboratory researcher in a file photo. Biotechnology company ImClone Systems said on Monday that a $60-per-share takeover bid from partner Bristol-Myers Squibb Co was too low, but it would hire financial advisers to help it study the unsolicited offer. (Sebastian Derungs/Reuters)" border="0" /></a>Reuters - Biotechnology company ImClone
Systems Inc said on Monday that a $60-per-share
takeover bid from partner Bristol-Myers Squibb Co was
too low, but it would hire financial advisers to help it study
the unsolicited offer.</p><br clear="all"/>

View the entire article: ImClone calls Bristol offer too low
(Reuters)